• Home
  • About GPCRCentral

GPCR News

Entries RSS | Comments RSS
  • Tags

    5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
  •  

    July 2008
    M T W T F S S
    « Jun   Aug »
     123456
    78910111213
    14151617181920
    21222324252627
    28293031  

NexMed receive non approvable letter for topical alprostadil

Posted on July 25, 2008 by crimsoncanary

NexMed have received a non approvable letter from the US FDA in response to its NDA for its topical alprostadil product Alprox-TD for for the treatment of erectile dysfunction (ED). The major regulatory issues raised by the FDA were related to the results of the transgenic mouse carcinogenicity study which NexMed completed in 2002.

Filed under: Uncategorized | Tagged: agonist, alprostadil, NexMed, PGE1, prostagland, Prostaglandin, Warner Chilcott

« Astellas publish series of Beta 3 adrenoceptor agonsits Vanda receive non approvable letter for Iloperidone »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • July 2008
      M T W T F S S
      « Jun   Aug »
       123456
      78910111213
      14151617181920
      21222324252627
      28293031  
  • Blogroll

    • CrimsonCanary.com
    • GPCRCentral.com
    • IonChannelCentral.com
    • Kinasecentral.com
    • Pharma Company Pipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer